Mavoglurant is an investigational drug candidate that acts as a selective mGlu5 receptor antagonist, primarily studied for its potential in treating conditions such as fragile X syndrome and Fragile X-associated… Read more
Mavoglurant is an investigational drug candidate that acts as a selective mGlu5 receptor antagonist, primarily studied for its potential in treating conditions such as fragile X syndrome and Fragile X-associated tremor/ataxia syndrome. Analytical laboratories utilize high-quality reference standards of this compound to support rigorous research, development, and quality control processes. This category includes the active pharmaceutical ingredient alongside its impurities and stable isotope labelled analogues, which are essential for precise analytical characterization. Researchers employ these reference materials for impurity profiling, method validation, and as internal standards in mass spectrometry to track metabolic pathways and pharmacokinetic outcomes. By providing access to these specialized compounds, analytical testing workflows can ensure compliance with regulatory standards throughout the preclinical and clinical development phases of this therapeutic agent.